An Angiotensin II Type 1 Receptor Blocker Prevents Renal Injury via Inhibition of the Notch Pathway in Ins2 Akita Diabetic Mice. (29th January 2012)

• Record Type: Journal Article
• Authors: Koshizaka, Masaya; Takemoto, Minoru; Sato, Seiya; Tokuyama, Hirotake; Fujimoto, Masaki; Okabe, Emiko; Ishibashi, Ryoichi; Ishikawa, Takahiro; Tsurutani, Yuya; Onishi, Shunichiro; Mezawa, Morito; He, Peng; Honjo, Satoshi; Ueda, Shiro; Saito, Yasushi; Yokote, Koutaro
• Other Names: Cooper Mark Emmanuel Academic Editor.
• Is Part Of: Experimental diabetes research. Volume 2012(2012)
• Publication Date: 2012-01-29
• Subjects: Diabetes -- Research -- Periodicals; Diabetes -- Research; Periodicals; 616.462
• DOI: 10.1155/2012/159874
• Languages: English
• ISSNs: 1687-5214

Abstract

Abstract : Recently, it has been reported that the Notch pathway is involved in the pathogenesis of diabetic nephropathy. In this study, we investigated the activation of the Notch pathway in Ins2 Akita diabetic mouse (Akita mouse) and the effects of telmisartan, an angiotensin II type1 receptor blocker, on the Notch pathway. The intracellular domain of Notch1 (ICN1) is proteolytically cleaved from the cell plasma membrane in the course of Notch activation. The expression of ICN1 and its ligand, Jagged1, were increased in the glomeruli of Akita mice, especially in the podocytes. Administration of telmisartan significantly ameliorated the expression of ICN1 and Jagged1. Telmisartan inhibited the angiotensin II-induced increased expression of transforming growth factor β and vascular endothelial growth factor A which could directly activate the Notch signaling pathway in cultured podocytes. Our results indicate that the telmisartan prevents diabetic nephropathy through the inhibition of the Notch pathway.